Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW’s FY2014 Budget Request Earmarks Funds to Expand Generic Drug Savings Notification Project to All Insurers
September 5, 2013
- Key Govt Council Sets Up 4 Subcommittees; Scraping of Insurance Coverage for OTC-Like Drugs Up for Discussion
September 4, 2013
- PAFSC Second Committee on Drugs to Discuss Hepatitis C Treatment Simeprevir at Meeting on September 13
September 3, 2013
- Diovan Panel Heats Up Over Future Course of Discussions; “Find Out Truth” vs “Identify Structural Flaws”
September 3, 2013
- MHLW Aims to Reduce Medical Expenditure by 1 Trillion Yen by FY2025 through Measures to Promote Generic Drug Use
September 2, 2013
- MHLW Adds Interstitial Pneumonia as Serious Adverse Reaction of Simponi
August 30, 2013
- 8% Sales Tax Will Be Tacked on Drug Market Prices, How It Will Be Shown Not Yet Agreed: MHLW Panel
August 30, 2013
- CSIMC’s DPC Subcommittee to Reconsider Use of Functional Evaluation Coefficient II to Evaluate Rate of Generic Drug Use
August 30, 2013
- MHLW’s Health Bureau to Seek 408.9 Billion Yen for 2014 Budget, 21.1 Billion for Infectious Disease Prevention
August 29, 2013
- HPB’s FY2014 Budget Request Earmarks Funds to Strength System of Hospitals that Accept All Emergency Patients
August 29, 2013
- University Hospitals Asked to Inspect Own Clinical Trials amid Diovan Jitters
August 28, 2013
- MHLW Budget Requests Feature 114.1 Billion Yen for Japan NIH, Drug Discovery Network
August 28, 2013
- MHLW’s Economic Affairs Division Honing in on “4th Round” of Distribution Reform; Era of Bundling Won’t Return
August 27, 2013
- Second Committee Recommends Approval for Japan’s First LABA/LAMA Combination Drug
August 27, 2013
- PMDA Provides Risk Information on 10 Ethical Drugs Currently Under Evaluation
August 27, 2013
- New Ethical Guidelines to Include Preventive Measures against Misconduct in Research: Health, Education Ministries’ Interim Report
August 26, 2013
- Council Calls for Sharper Price Reductions for Long-Listed Drugs, Increase in Operating Profit Rate When Using Cost Calculation Method
August 26, 2013
- Applicants Objected to Proposed NHI Prices for 16 APIs in April 2010-May 2013; Revisions Made for 5 APIs
August 26, 2013
- First Committee Recommends Approval of Takeda’s Anti-Obesity Drug OBLEAN, Other Products
August 26, 2013
- Bill Payer and Healthcare Reps Support MHLW Proposal to Reduce NHI Prices; Industry Reps Want a Hold on a Decision
August 26, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…